ATYR Atyr Pharma Inc

Price (delayed)

$1.74

Market cap

$120.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

$124.18M

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly ...

Highlights
ATYR's EPS is up by 38% year-on-year and by 4.3% since the previous quarter
The debt has contracted by 6% from the previous quarter
The revenue has shrunk by 94% YoY but it has soared by 67% QoQ
The company's gross profit has shrunk by 94% YoY but it has surged by 67% QoQ
Atyr Pharma's quick ratio has decreased by 35% YoY and by 11% from the previous quarter
The company's equity fell by 23% YoY and by 7% QoQ

Key stats

What are the main financial stats of ATYR
Market
Shares outstanding
69.01M
Market cap
$120.08M
Enterprise value
$124.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.4
Price to sales (P/S)
195.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
211.2
Earnings
Revenue
$588,000
EBIT
-$53.93M
EBITDA
-$51.17M
Free cash flow
-$57.98M
Per share
EPS
-$0.9
Free cash flow per share
-$0.88
Book value per share
$1.25
Revenue per share
$0.01
TBVPS
$1.71
Balance sheet
Total assets
$113.25M
Total liabilities
$28.97M
Debt
$14.13M
Equity
$84.47M
Working capital
$80.94M
Liquidity
Debt to equity
0.17
Current ratio
6.07
Quick ratio
5.64
Net debt/EBITDA
-0.08
Margins
EBITDA margin
-8,702.9%
Gross margin
100%
Net margin
-9,171.6%
Operating margin
-9,994.6%
Efficiency
Return on assets
-43.9%
Return on equity
-56.8%
Return on invested capital
-50.3%
Return on capital employed
-55.4%
Return on sales
-9,171.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATYR stock price

How has the Atyr Pharma stock price performed over time
Intraday
7.41%
1 week
15.23%
1 month
-8.42%
1 year
-13%
YTD
23.4%
QTD
11.54%

Financial performance

How have Atyr Pharma's revenue and profit performed over time
Revenue
$588,000
Gross profit
$588,000
Operating income
-$58.77M
Net income
-$53.93M
Gross margin
100%
Net margin
-9,171.6%
The revenue has shrunk by 94% YoY but it has soared by 67% QoQ
The company's gross profit has shrunk by 94% YoY but it has surged by 67% QoQ
The net margin has grown by 36% from the previous quarter
ATYR's operating margin is up by 36% since the previous quarter

Growth

What is Atyr Pharma's growth rate over time

Valuation

What is Atyr Pharma stock price valuation
P/E
N/A
P/B
1.4
P/S
195.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
211.2
ATYR's EPS is up by 38% year-on-year and by 4.3% since the previous quarter
ATYR's P/B is 27% above its 5-year quarterly average of 1.1 and 27% above its last 4 quarters average of 1.1
The company's equity fell by 23% YoY and by 7% QoQ
The revenue has shrunk by 94% YoY but it has soared by 67% QoQ
ATYR's P/S is 73% above its last 4 quarters average of 113.3

Efficiency

How efficient is Atyr Pharma business performance
ATYR's ROS is up by 36% since the previous quarter
The return on equity has declined by 14% since the previous quarter and by 9% year-on-year
The ROA has contracted by 12% from the previous quarter and by 3.3% YoY
The company's return on invested capital fell by 10% QoQ but it rose by 3.6% YoY

Dividends

What is ATYR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATYR.

Financial health

How did Atyr Pharma financials performed over time
Atyr Pharma's quick ratio has decreased by 35% YoY and by 11% from the previous quarter
The current ratio has contracted by 31% YoY and by 3.2% from the previous quarter
The debt is 83% less than the equity
ATYR's debt to equity is up by 31% YoY
The company's equity fell by 23% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.